Josef Kletzmayr - Publications

Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial.

Journal: ESC heart failure

Published: February 03, 2026

Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 17, 2021

Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis.

Journal: Atherosclerosis

Published: September 27, 2019

Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI).

Journal: Thrombosis research

Published: April 19, 2017

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI).

Journal: PloS one

Published: August 01, 2016

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: March 19, 2015

Pre-implant biopsy predicts outcome of single-kidney transplantation independent of clinical donor variables.

Journal: Transplantation

Published: November 29, 2013

Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients.

Journal: European journal of clinical investigation

Published: August 01, 2012